MarketLine Blog

Posts tagged to Pharmaceuticals

Global generics market to experience double-digit growth through to 2021, says MarketLine

MarketLine

The global generics market has experienced dynamic growth in recent years, registering a compound annual growth rate (CAGR) of 11.1% between 2012 and 2016 to reach a value of $318 billion, according to data from research company MarketLine. The company’s latest report states that Asia-Pacific was comfortably the largest region in value terms, accounting for over 46% of the global total in 2016. The US followed with over 31%, while Europe continued to lag behind, contributing only 15.6%. The US once again reigned supreme as the single biggest country market,… Read more

Pfizer re-entring to the OTC healthcare market

MarketLine

Pfizer Inc., the world’s largest pharmaceutical company, exited the over-the-counter (OTC) healthcare market in 2006 with the sale of its Consumer Healthcare division to Johnson & Johnson. Just 3 years later, in 2009, Pfizer re-entered the market with its acquisition of Wyeth. This article will examine the rise of Pfizer into a diversified healthcare company, the circumstances that led to the disposal of the Consumer Healthcare division, and the subsequent re-entry to the OTC market in 2009. Pfizer, Inc. was originally founded as fine chemicals business. Following a series of… Read more

Remicade, a Biotech Blockbuster in Treating a Variety of Immune System Diseases

MarketLine

Remicade is a drug used in treating a variety of immune system diseases, and its active ingredient is produced through biotechnology.  Johnson & Johnson reported Remicade sales of $4.6 bn in 2010, and the drug is the best-selling “biologic” in the world. This article examines its long journey from an academic research laboratory to a leading position in the pharmaceutical market. In 2010, the world’s best-selling biologic drug was Remicade. Since its original US Food and Drug Administration (FDA) approval as a treatment for Crohn’s disease in 1998, global sales… Read more

Dexcom Case Study: Launching a Continuous Glucose Monitor

MarketLine

Continuous glucose monitors (CGMs) promise certain diabetics more effective self-management of their condition. Medtronic is a leading US supplier of CGMs, but since 2006 it has faced competition from a small start-up, Dexcom. Management of diabetes often requires electronic blood glucose testing. Until recently, this was done using meters that offered single measurements. Continuous monitors came on to the US market in 2001 and offer certain diabetics the prospect of improved management of their condition, by detecting abnormal glucose levels more rapidly. Medtronic and Dexcom are the only players in… Read more

The OTC Healthcare Market has Become Increasingly Attractive in Recent Years

MarketLine

In recent years, a number of major healthcare companies including Pfizer, Roche, and Bristol-Myers Squibb (BMS) have sold their over-the-counter (OTC) healthcare divisions in a bid to focus their attention on pharmaceuticals. Bayer acquired Roche Consumer Health in 2004, while BMS sold its OTC unit to Novartis in 2005. Pfizer sold its Consumer Healthcare business to Johnson & Johnson in 2006. However, more recently this trend has reversed with companies re-entering the OTC healthcare market. For example, Pfizer marked its re-entry to the market in 2009 with its acquisition of… Read more

Generics Market – Likely To Continue to produce good growth through to 2016

  The global generics market has produced good growth in recent years and, due to the trend of cheaper generics replacing branded pharmaceutical products when patents end, the market is likely to continue to produce good growth through to 2016. The last few years have seen a number of blockbuster drugs coming to the end of their patents, which has shown the speed with which generics can be introduced and dominate a previously locked up market. This change is happening because the switch to generics from branded drugs is highly… Read more